Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wataru Obara

Showing results (101-110 of 170) with videos related to

Pageof 17
Sort By:
Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy|December 13, 2023
Abnormal carnitine metabolism in hemodialysis patients on different anticoagulantsKie Sekiguchi, Takaya Abe, Ei Shiomi, et al.
Translational Oncology|May 7, 2020
Analyses of Nivolumab Exposure and Clinical Safety Between 3-mg/kg Dosing and 240-mg Flat Dosing in Asian Patients with Advanced Renal Cell Carcinoma in the Real-World Clinical SettingRenpei Kato, Daiki Ikarashi, Tomohiko Matsuura, et al.
The International Journal of Medical Robotics + Computer Assisted Surgery : MRCAS|May 2, 2026
Perioperative Outcomes of Robot-Assisted Partial Nephrectomy Using Hinotori Compared With da Vinci Xi: A Propensity Score-matched AnalysisMitsugu Kanehira, Yasushi Nozaki, Keita Ogasawara, et al.
Japanese Journal of Clinical Oncology|August 3, 2022
Real-world effectiveness of nivolumab plus ipilimumab and second-line therapy in Japanese untreated patients with metastatic renal cell carcinoma: 2-year analysis from a multicenter retrospective clinical study (J-cardinal study)Takahiro Kojima, Renpei Kato, Tomokazu Sazuka, et al.
Anticancer Research|December 1, 2021
A Multicentre Retrospective Study of Nivolumab Plus Ipilimumab for Untreated Metastatic Renal Cell CarcinomaRenpei Kato, Takahiro Kojima, Tomokazu Sazuka, et al.
Cancer Immunology, Immunotherapy : CII|January 27, 2026
Immunological profile of the tumor immune microenvironment of upper tract urothelial carcinoma predicts recurrence patternsKenta Takahashi, Daiki Ikarashi, Shigehisa Kitano, et al.
Scientific Reports|January 16, 2024
Pathological complete response to neoadjuvant chemotherapy may improve antitumor immune response via reduction of regulatory T cells in muscle-invasive bladder cancerDaiki Ikarashi, Shigehisa Kitano, Takashi Tsuyukubo, et al.
Hinyokika Kiyo. Acta Urologica Japonica|September 5, 2023
[A Case of Metastatic Renal Cell Carcinoma with Arthritis and Colitis Due to Immune-Related Adverse Events During Ipilimumab-Nivolumab Combination Therapy]Moe Toyoshima, Daiki Ikarashi, Hiroyuki Tsuboi, et al.
Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy|March 31, 2018
Pelvic Artery Calcification Score Is a Marker of Vascular Calcification in Male Hemodialysis PatientsTomohiko Matsuura, Takaya Abe, Mitsutaka Onoda, et al.
Frontiers in Oncology|February 13, 2025
Tumor-shrinking effects of enfortumab vedotin between primary urothelial carcinoma and metastatic organsDaiki Ikarashi, Tatsuya Kawamura, Keita Ogasawara, et al.
Pageof 17

Showing results (101-110 of 170) with videos related to

Sort By:
Pageof 17
Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy|December 13, 2023
Abnormal carnitine metabolism in hemodialysis patients on different anticoagulantsKie Sekiguchi, Takaya Abe, Ei Shiomi, et al.
Translational Oncology|May 7, 2020
Analyses of Nivolumab Exposure and Clinical Safety Between 3-mg/kg Dosing and 240-mg Flat Dosing in Asian Patients with Advanced Renal Cell Carcinoma in the Real-World Clinical SettingRenpei Kato, Daiki Ikarashi, Tomohiko Matsuura, et al.
The International Journal of Medical Robotics + Computer Assisted Surgery : MRCAS|May 2, 2026
Perioperative Outcomes of Robot-Assisted Partial Nephrectomy Using Hinotori Compared With da Vinci Xi: A Propensity Score-matched AnalysisMitsugu Kanehira, Yasushi Nozaki, Keita Ogasawara, et al.
Japanese Journal of Clinical Oncology|August 3, 2022
Real-world effectiveness of nivolumab plus ipilimumab and second-line therapy in Japanese untreated patients with metastatic renal cell carcinoma: 2-year analysis from a multicenter retrospective clinical study (J-cardinal study)Takahiro Kojima, Renpei Kato, Tomokazu Sazuka, et al.
Anticancer Research|December 1, 2021
A Multicentre Retrospective Study of Nivolumab Plus Ipilimumab for Untreated Metastatic Renal Cell CarcinomaRenpei Kato, Takahiro Kojima, Tomokazu Sazuka, et al.
Cancer Immunology, Immunotherapy : CII|January 27, 2026
Immunological profile of the tumor immune microenvironment of upper tract urothelial carcinoma predicts recurrence patternsKenta Takahashi, Daiki Ikarashi, Shigehisa Kitano, et al.
Scientific Reports|January 16, 2024
Pathological complete response to neoadjuvant chemotherapy may improve antitumor immune response via reduction of regulatory T cells in muscle-invasive bladder cancerDaiki Ikarashi, Shigehisa Kitano, Takashi Tsuyukubo, et al.
Hinyokika Kiyo. Acta Urologica Japonica|September 5, 2023
[A Case of Metastatic Renal Cell Carcinoma with Arthritis and Colitis Due to Immune-Related Adverse Events During Ipilimumab-Nivolumab Combination Therapy]Moe Toyoshima, Daiki Ikarashi, Hiroyuki Tsuboi, et al.
Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy|March 31, 2018
Pelvic Artery Calcification Score Is a Marker of Vascular Calcification in Male Hemodialysis PatientsTomohiko Matsuura, Takaya Abe, Mitsutaka Onoda, et al.
Frontiers in Oncology|February 13, 2025
Tumor-shrinking effects of enfortumab vedotin between primary urothelial carcinoma and metastatic organsDaiki Ikarashi, Tatsuya Kawamura, Keita Ogasawara, et al.
Pageof 17